Skip to main content

Table 1 Clinicopathological characteristics of patients with MRTK.

From: Clinical and prognostic analysis of 42 children with malignant rhabdoid tumor of the kidney: a 7-year retrospective multi-center study

 

Total

Alive

Dead

P

 

42

11

31

Sex (%)

    

1

25 (59.52)

6 (54.55)

19 (61.29)

0.9728

2

17 (40.48)

5 (45.45)

12 (38.71)

 

Age (%)

    

≤ 12 months

22 (52.38)

3 (27.27)

19 (61.29)

0.112

> 12 months

20 (47.62)

8 (72.73)

12 (38.71)

 

Metastasis at diagnosis (%)

    

No

33 (78.57)

11 (100.00)

22 (70.97)

0.1122

Yes

9 (21.43)

0 (0.00)

9 (29.03)

 

Fever (%)

    

No

31 (73.81)

9 (81.82)

22 (70.97)

0.7611

Yes

11 (26.19)

2 (18.18)

9 (29.03)

 

Anemia (%)

    

No

28 (66.67)

11 (100.00)

17 (54.84)

0.0184

Yes

14 (33.33)

0 (0.00)

14 (45.16)

 

Hematuresis (%)

    

No

27 (64.29)

7 (63.64)

20 (64.52)

1

Yes

15 (35.71)

4 (36.36)

11 (35.48)

 

Hypertension (%)

    

No

38 (90.48)

10 (90.91)

28 (90.32)

1

Yes

4 (9.52)

1 (9.09)

3 (9.68)

 

Hypercalcemia (%)

    

No

38 (90.48)

11 (100.00)

27 (87.10)

0.5127

Yes

4 (9.52)

0 (0.00)

4 (12.90)

 

Preoperative chemotherapy (%)

    

No

33 (78.57)

10 (90.91)

23 (74.19)

0.4635

Yes

9 (21.43)

1 (9.09)

8 (25.81)

 

Tumor size (mean (SD))

9.112 (3.908)

8.518 (4.622)

9.323 (3.684)

0.564

Operation time (mean (SD))

115.071 (34.384)

121.273 (37.227)

112.871 (33.686)

0.4931

Hemorrhage (median [IQR])

70 [20, 200]

35 [20, 110]

100[35, 200]

0.172

Tumor location (%)

    

Full

9 (21.43)

1 (9.09)

8 (25.81)

0.0131

Upper

16 (38.10)

5 (45.45)

11 (35.48)

 

Middle

14 (33.33)

2 (18.18)

12 (38.71)

 

Lower

3 (7.14)

3 (27.27)

0 (0.00)

 

Tumor side (%)

    

Left

22 (52.38)

7 (63.64)

15 (48.39)

0.604

Right

20 (47.62)

4 (36.36)

16 (51.61)

 

Cross the center line (%)

    

No

21 (50.00)

4 (36.36)

17 (54.84)

0.4827

Yes

21 (50.00)

7 (63.64)

14 (45.16)

 

Tumor rupture (%)

    

No

27 (64.29)

8 (72.73)

19 (61.29)

0.7536

Yes

15 (35.71)

3 (27.27)

12 (38.71)

 

Capsule (%)

    

No

19 (45.24)

8 (72.73)

11 (35.48)

0.0751

Yes

23 (54.76)

3 (27.27)

20 (64.52)

 

Incomplete tumor resection (%)

    

No

36 (85.71)

11 (100.00)

25 (80.65)

0.2826

Yes

6 (14.29)

0 (0.00)

6 (19.35)

 

Tumor embolus (%)

    

No

34 (80.95)

9 (81.82)

25 (80.65)

1

Yes

8 (19.05)

2 (18.18)

6 (19.35)

 

Infiltration (%)

    

No

30 (71.43)

9 (81.82)

21 (67.74)

0.6175

Yes

12 (28.57)

2 (18.18)

10 (32.26)

 

Lymph node metastasis (%)

    

No

37 (88.10)

11 (100.00)

26 (83.87)

0.3803

Yes

5 (11.90)

0 (0.00)

5 (16.13)

 

Tumor stage (%)

    

I

6 (14.29)

4 (36.36)

2 (6.45)

0.0269

II

5 (11.90)

2 (18.18)

3 (9.68)

 

III

21 (50.00)

5 (45.45)

16 (51.61)

 

IV

10 (23.81)

0 (0.00)

10 (32.26)

 

Preoperative chemotherapy (%)

    

No

30 (71.43)

9 (81.82)

21 (67.74)

0.6175

Yes

12 (28.57)

2 (18.18)

10 (32.26)

 

Chemotherapy protocol (%)

    

No

12 (28.57)

2 (18.18)

10 (32.26)

0.6743

VDACE

10 (23.81)

3 (27.27)

7 (22.58)

 

HU-1

20 (47.62)

6 (54.55)

14 (45.16)

 

Preoperative metastasis (%)

    

No

18 (42.86)

11 (100.00)

7 (22.58)

< 0.0001

Yes

24 (57.14)

0 (0.00)

24 (77.42)

Â